Sabby Management’s Tenax Therapeutics TENX Stock Holding History

Sabby Management’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Hold	–	-$2.39M	–	311
2016 Q4	–	Hold	–	–	–	91
2016 Q3	–	Hold	–	–	–	214
2016 Q2	–	Hold	–	–	–	266
2016 Q1	–	Hold	–	–	–	287
2015 Q3	–	Hold	–	-$12.2M	–	400
2015 Q2	–	Hold	–	–	–	47
2014 Q3	–	Hold	–	-$244K	–	290
2014 Q2	–	Hold	–	–	–	220
2014 Q1	–	Hold	–	–	–	212

Other funds holding TENX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sabby Management's TENX Position: Q2 2020 in Review

Sabby Management sold out of Tenax Therapeutics (TENX) in Q2 2020, closing a stake of 21 shares — an estimated $19K sold.

Sabby Management first reported a position in TENX in Q3 2013 and held it in 17 quarters. The position peaked at $11.8M in Q1 2014. 17 funds tracked by Wall St. Rank hold TENX as of Q2 2020.

Sabby Management reported no remaining Tenax Therapeutics position as of Q2 2020 after selling out during the quarter.
Sabby Management sold 21 Tenax Therapeutics shares in Q2 2020, an estimated $19K.
Sabby Management first reported a position in Tenax Therapeutics in Q3 2013 and held it in 17 quarters.
Sabby Management's Tenax Therapeutics position peaked at $11.8M in Q1 2014.
17 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2020.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.